Analysts Set Novartis AG (NYSE:NVS) PT at $100.50

Shares of Novartis AG (NYSE:NVS) have earned a consensus rating of “Hold” from the twelve research firms that are currently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $100.50.

Several brokerages have recently commented on NVS. UBS Group restated a “buy” rating on shares of Novartis in a research note on Friday, October 8th. JPMorgan Chase & Co. restated an “underweight” rating on shares of Novartis in a research note on Wednesday, July 28th. Zacks Investment Research downgraded Novartis from a “hold” rating to a “sell” rating and set a $96.00 target price for the company. in a research note on Monday, July 26th. Deutsche Bank Aktiengesellschaft downgraded Novartis from a “hold” rating to a “sell” rating in a research note on Monday, September 20th. Finally, Berenberg Bank restated a “buy” rating on shares of Novartis in a research note on Tuesday.

Shares of NVS stock traded up $0.18 during mid-day trading on Friday, hitting $82.61. The company’s stock had a trading volume of 52,871 shares, compared to its average volume of 1,916,302. The company’s fifty day simple moving average is $87.73 and its 200-day simple moving average is $88.99. Novartis has a 52 week low of $77.04 and a 52 week high of $98.52. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.56 and a current ratio of 0.80. The company has a market cap of $184.78 billion, a PE ratio of 20.91, a P/E/G ratio of 2.07 and a beta of 0.54.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Tuesday, July 20th. The company reported $1.66 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.52 by $0.14. Novartis had a return on equity of 25.25% and a net margin of 17.83%. The firm had revenue of $12.96 billion during the quarter, compared to analyst estimates of $12.41 billion. During the same period last year, the company posted $1.36 EPS. The business’s quarterly revenue was up 14.2% on a year-over-year basis. On average, equities analysts anticipate that Novartis will post 6.28 earnings per share for the current year.

Large investors have recently bought and sold shares of the stock. Evermay Wealth Management LLC bought a new stake in shares of Novartis in the 2nd quarter worth approximately $30,000. Allworth Financial LP raised its holdings in shares of Novartis by 76.0% in the 2nd quarter. Allworth Financial LP now owns 403 shares of the company’s stock worth $37,000 after purchasing an additional 174 shares during the period. RMR Wealth Builders raised its holdings in shares of Novartis by 222.7% in the 1st quarter. RMR Wealth Builders now owns 455 shares of the company’s stock worth $39,000 after purchasing an additional 314 shares during the period. Anfield Capital Management LLC bought a new stake in shares of Novartis in the 2nd quarter worth approximately $42,000. Finally, Parisi Gray Wealth Management bought a new stake in shares of Novartis in the 2nd quarter worth approximately $44,000. 9.90% of the stock is currently owned by institutional investors.

About Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals.

Featured Article: Operating Income

Analyst Recommendations for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.